Key result
Within one year of cancer diagnosis, treatment discontinuation was 26% for DOACs compared to 61% for warfarin, and switching was also less common for DOACs (1.7% vs 8.6%).
Why the study?
Data on the use of oral anti-coagulants for stroke prevention in cancer patients with AF were sparse.
What are the treatment patterns, switching, and discontinuation rates of oral anti-coagulants in patients with atrial fibrillation newly diagnosed with cancer?
Cohort (n=12,756)
Yes
What are the treatment patterns, switching, and discontinuation rates of oral anti-coagulants in patients with atrial fibrillation newly diagnosed with cancer?
Absolute Event Rate: 26% vs 61%
In patients with atrial fibrillation newly diagnosed with cancer, DOACs are associated with significantly lower rates of discontinuation and switching compared to warfarin.
OAC use patterns post-cancer diagnosis in AF merit prospective evaluation; leaves open optimal strategies in this population.
Data on the use of oral anti-coagulants (OAC) for stroke prevention in cancer patients with atrial fibrillation (AF) are sparse. Nationwide cohort study of patients with AF (2012-2018) and an indication for OAC who were diagnosed with cancer at least one year later (N = 12 756). We identified treatment with OAC at cancer diagnosis and the following year and described the incidence of discontinuing or switching between warfarin and direct oral anti-coagulants (DOACs). We also described baseline characteristics associated with OAC non-persistence. One third of the cancer patients received no OAC therapy, whereas 42% received warfarin and 24% received DOAC treatment. Switching incidence between OACs was higher for those receiving warfarin treatment (8.6%) than DOAC treatment (1.7%) within one year. Treatment discontinuation was 61% for warfarin and 26% for DOAC. Females were less likely to discontinue DOAC than males (ratio 0.77, 95% confidence interval: 0.66, 0.90). Increasing cancer stage was associated with discontinuation of DOAC, but not warfarin. OAC for stroke prevention in AF was used by two thirds of patients with newly diagnosed cancer. Switching between OACs and discontinuation was more common for warfarin than DOAC, and females had higher persistence with DOACs.
No takes yet. Share an insight, caveat, or question.
Ording et al. (2022) conducted a cohort in Atrial fibrillation and cancer (n=12,756). DOACs vs. Warfarin was evaluated on Treatment discontinuation within one year. Within one year of cancer diagnosis, treatment discontinuation was 26% for DOACs compared to 61% for warfarin, and switching was also less common for DOACs (1.7% vs 8.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: